4 - GENELUX Corp (0001231457) (Issuer)

3 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

Lake Street initiated coverage of Genelux with a rating of Buy and set a new price target of $16.00

Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00

H.C. Wainwright initiated coverage of Genelux with a rating of Buy and set a new price target of $35.00

Maxim Group initiated coverage of Genelux with a rating of Buy and set a new price target of $40.00

The Benchmark Company initiated coverage of Genelux with a rating of Speculative Buy and set a new price target of $10.00

8-K - GENELUX Corp (0001231457) (Filer)

424B5 - GENELUX Corp (0001231457) (Filer)

424B5 - GENELUX Corp (0001231457) (Filer)

8-K - GENELUX Corp (0001231457) (Filer)

8-K - GENELUX Corp (0001231457) (Filer)

10-Q - GENELUX Corp (0001231457) (Filer)

8-K - GENELUX Corp (0001231457) (Filer)

S-8 - GENELUX Corp (0001231457) (Filer)

10-Q - GENELUX Corp (0001231457) (Filer)

DEFA14A - GENELUX Corp (0001231457) (Filer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be sold by Genelux. The gross proceeds to Genelux from the offering are expected to be approximately $20.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. In addition, Genelux has granted the underwriter a 30-day option to purchase up to an additional 1,000,000 shares of its common s

WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten public offering of its common stock. In addition, Genelux expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the proposed offering. All shares are being offered by Genelux. The proposed offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of

-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In platinum-relapsed or platinum-refractory advanced SCLC, two of three partial responses (PRs) occurred in the highest dose cohort tested as of the data review cutoff date (tumor shrinkage of ~55% and ~85%), with three PRs out of nine subjects (33%) across all dose cohorts; observed durable response signals and treatment tolerability (Phase 1b/2 SCLC) -- -- In advanced or metastatic recurrent NSCLC, observed anti-tumor activity in initial dose cohort and Olvi-Vec generally wel

WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati

WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York, NY. A live webcast of the fireside chat can be found here. Following the live webcast, an archived replay will be available on the Company's website https://investors.genelux.com/. About Genelux Corporation Genelux is a late clinical-stage biopharmaceutical company focused on d

-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- Cash, cash equivalents, short-term investments and restricted cash of $21.0 million as of September 30, 2025 -- WESTLAKE VILLAGE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2025 and provided general business updates. "In the third quarter, we continued to progress Olvi-Vec's development across multiple solid tumor indications, positioning the p

WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at H.C. Wainwright & Co's Annual Global Investment Conference on Tuesday, September 9, 2025. Biotech Equity Research Analyst, Emily Bodnar, will moderate the session which is scheduled to begin at 2:30 p.m. ET. To register for and view the session, please use the link https://journey.ct.events/view/6248b37e-6c86-47e2-8bd2-0e03637b46e4. An archived replay will be available for approximately 90

WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. Genelux continues to advance Olvi-Vec toward potential registration in platinum-resistant/refractory ovarian cancer (PRROC) with topline data expected in the first half of 2026. Earlier this

WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. "We are delighted to welcome Eric to the executive team," said Thomas Zindrick, President, CEO, and Chairman of the Board. "Eric brings a powerful blend of legal expertise, global business development savvy, and a strategic understanding of the biotechnology ecosystem. His proven ability to lead high-impact transactions, build trusted partnerships, and navigate complex regulatory

WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates.   "The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications, with encouraging regulatory feedback from the FDA on our OnPrime Phase 3 registrational trial in resistant/refractory ovarian cancer, promising early lung cancer clinical data from our ongoing Phase 1b/2 study, and increasing patient enrollment in our U.S. Ph

WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati

WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. Genelux continues to advance Olvi-Vec toward potential registration in platinum-resistant/refractory ovarian cancer (PRROC) with topline data expected in the first half of 2026. Earlier this

WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. "We are delighted to welcome Eric to the executive team," said Thomas Zindrick, President, CEO, and Chairman of the Board. "Eric brings a powerful blend of legal expertise, global business development savvy, and a strategic understanding of the biotechnology ecosystem. His proven ability to lead high-impact transactions, build trusted partnerships, and navigate complex regulatory

WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. "I am very pleased to welcome Matt as our new Chief Financial Officer. Matt's financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux," said Thomas Zindrick, President, CEO and Chairman of the Board. "His unique combination of financial expertise and scientific background will be valuable as the company continues building towards the potential launch of Olvi-Vec." Mr. Pulisic is an ac

Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

SC 13G - GENELUX Corp (0001231457) (Subject)

SC 13G/A - GENELUX Corp (0001231457) (Subject)

SC 13G - GENELUX Corp (0001231457) (Subject)

SC 13G - GENELUX Corp (0001231457) (Subject)